Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Preclinical and clinical development of immunocytokines.

Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR.

Curr Opin Investig Drugs. 2003 Jun;4(6):696-700. Review.

PMID:
12901228
[PubMed - indexed for MEDLINE]
2.

What does it take to make a natural killer?

Colucci F, Caligiuri MA, Di Santo JP.

Nat Rev Immunol. 2003 May;3(5):413-25. Review.

PMID:
12766763
[PubMed - indexed for MEDLINE]
3.

Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine.

Hank JA, Surfus JE, Gan J, Ostendorf A, Gillies SD, Sondel PM.

Methods Mol Med. 2003;85:123-31. Review. No abstract available.

PMID:
12710203
[PubMed - indexed for MEDLINE]
4.

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ.

J Clin Oncol. 2001 Oct 1;19(19):3976-87.

PMID:
11579119
[PubMed - indexed for MEDLINE]
Free Article
5.

Progress in human tumour immunology and immunotherapy.

Rosenberg SA.

Nature. 2001 May 17;411(6835):380-4. Review.

PMID:
11357146
[PubMed - indexed for MEDLINE]
6.
7.

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.

Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 1999 Aug;48(5):219-29.

PMID:
10478638
[PubMed - indexed for MEDLINE]
8.

Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.

Gan J, Kendra K, Ricci M, Hank JA, Gillies SD, Sondel PM.

Clin Diagn Lab Immunol. 1999 Mar;6(2):236-42.

PMID:
10066660
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1996 Dec;2(12):1951-9.

PMID:
9816154
[PubMed - indexed for MEDLINE]
Free Article
10.

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, Bechhofer R, Storer B, Reisfeld RA, Sondel PM.

Clin Cancer Res. 1997 Aug;3(8):1277-88.

PMID:
9815810
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Yu AL, Uttenreuther-Fischer MM, Huang CS, Tsui CC, Gillies SD, Reisfeld RA, Kung FH.

J Clin Oncol. 1998 Jun;16(6):2169-80.

PMID:
9626218
[PubMed - indexed for MEDLINE]
Free Article
12.

Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.

Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA.

Blood. 1998 Mar 1;91(5):1706-15.

PMID:
9473237
[PubMed - indexed for MEDLINE]
Free Article
13.

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA.

J Natl Cancer Inst. 1997 Nov 5;89(21):1586-94.

PMID:
9362156
[PubMed - indexed for MEDLINE]
Free Article
14.

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM.

Cancer. 1997 Jul 15;80(2):317-33.

PMID:
9217046
[PubMed - indexed for MEDLINE]
15.

Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15.

Farner NL, Gan J, de Jong JL, Leary TP, Fenske TS, Buckley P, Dunlap S, Sondel PM.

Cytokine. 1997 May;9(5):316-27.

PMID:
9195130
[PubMed - indexed for MEDLINE]
16.

Diabetes mellitus induced by low-dose interleukin-2.

Soni N, Meropol NJ, Porter M, Caligiuri MA.

Cancer Immunol Immunother. 1996 Sep;43(1):59-62.

PMID:
8917637
[PubMed - indexed for MEDLINE]
17.

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.

Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA.

J Exp Med. 1996 May 1;183(5):2361-6.

PMID:
8642346
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.

Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA.

Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7.

PMID:
8610104
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.

Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.

J Immunol. 1987 Mar 15;138(6):1992-8.

PMID:
3493293
[PubMed - indexed for MEDLINE]
20.

Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA.

Clin Nephrol. 1988 Sep;30(3):141-5.

PMID:
3263237
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk